vankomicin actavis 500 mg prašek za koncentrat za raztopino za infundiranje
actavis group ptc ehf. - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 500 mg / 1 viala - vankomicin
vankomicin actavis 1000 mg prašek za koncentrat za raztopino za infundiranje
actavis group ptc ehf. - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin
klopidogrel actavis 75 mg filmsko obložene tablete
actavis group ptc ehf. - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel
klopidogrel actavis 75 mg filmsko obložene tablete
actavis group ptc ehf. - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel
pioglitazone actavis
actavis group ptc ehf - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena (glej poglavje 4.
rivastigmine actavis
actavis group ptc ehf - rivastigminijev hidrogentartrat - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - simptomatsko zdravljenje blage do zmerno hude alzheimerjeve demence. simptomatsko zdravljenje blage do zmerno hude demence pri bolnikih z idiopatsko parkinsonovo boleznijo.
telmisartan actavis
actavis group ptc ehf - telmisartan - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - hypertensiontreatment bistvenih hipertenzije pri odraslih. kardiovaskularni preventionreduction za srčno-žilne obolevnosti pri bolnikih z:manifest atherothrombotic bolezni srca in ožilja (zgodovina bolezni srca in ožilja, kap, ali periferne arterijske bolezni) ali;tip 2 sladkorna bolezen z dokumentiranimi ciljni organ škode.
bortezomib actavis 3,5 mg prašek za raztopino za injiciranje
actavis group ptc ehf. - bortezomib - prašek za raztopino za injiciranje - bortezomib 3,5 mg / 1 viala - bortezomib
olanzapin actavis 10 mg orodisperzibilne tablete
actavis group ptc ehf. - olanzapin - orodisperzibilna tableta - olanzapin 10 mg / 1 tableta - olanzapin
olanzapin actavis 5 mg orodisperzibilne tablete
actavis group ptc ehf. - olanzapin - orodisperzibilna tableta - olanzapin 5 mg / 1 tableta - olanzapin